
Covid vaccine stocks, including Moderna, BioNTech, and Novavax have all closed higher as new vaccinations and treatments roll out.
Novavax creates recombinant protein nanoparticle vaccines to address a broad range of infectious diseases.
Novavax, Inc. is a clinical-stage vaccine company headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax received a US$89 million research grant from the Bill and Melinda Gates Foundation for development of vaccines for maternal immunization. It has an ongoing Phase III clinical trial in older adults for its candidate vaccine for seasonal influenza, NanoFlu. The company positions NanoFlu for the unmet need for a more effective vaccine against influenza, particularly in the elderly who often experience serious and sometimes life-threatening complications. In January 2020, it was granted fast track status by the US Food and Drug Administration (FDA) for NanoFlu.
Covid vaccine stocks, including Moderna, BioNTech, and Novavax have all closed higher as new vaccinations and treatments roll out.
In Tuesday’s post-trading session, biotech firm Novavax saw its stock surge following “significant measures” taken to operate more efficiently.
Novavax has some key meetings ahead with the US Food and Drug Administration next month for the approval of its two-dose vaccine in the US.